Product

Company

NCT01728909·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of California, San Francisco

With

Age

18–any

Sex

MALE

Healthy volunteers

Accepted

Primary diagnosis of opioid dependence according to DSM-IV TR
Opioid of choice be either heroin or oral opioid analgesics
Currently be on stable dose of methadone with no dose change in the last 14 days
No diagnosis of mental disorder according to DSM-IV TR

Epilepsy
Current illicit drug use (within the past one month)
Current sever depression with suicidal thoughts and/or actions
Addiction to alcohol or drugs other than opiates, caffeine, or nicotine
Psychotic illness
Bipolar disorder
Brain trauma
Severe Neuropsychological disorder
Kidney Disease (i.e., kidney stones, recurrent bladder infections, or known kidney failure)
Sensitivity to preservatives (in particular E216, E218, and chlorobutanol hemihydrate)
Nasal obstruction, discharge, or bleeding
Cardiovascular problems (e.g., heart disease, history of heart attacks), high blood pressure (hypertension)
Habitually drink large volumes of water

The record

StatusCompleted

PhaseEarly phase 1

Taking part64

StartedMay 2012

UpdatedMay 21, 2019

Conditions

Where1

Clareo Health | Methadone Oxytocin Option